Related Experiment Video

Updated: Aug 30, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

Role of Phosphatidylinositol 3-Kinase and Its Catalytic Unit PIK3CA in Cervical Cancer: A Mini-Review

Guojuan Sun1, Qiang Zhang1, Yi Liu2

  • 1Ward Section of Home Overseas Doctors, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.

Applied Bionics and Biomechanics
|September 1, 2022
PubMed

Insights

The phosphoinositol 3-kinase (PI3K) pathway is crucial in cervical cancer. Targeting PI3K, especially PIK3CA, offers a promising therapeutic strategy for this complex disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Signaling pathways in cancer are complex networks, often leading to treatment resistance.
  • The phosphoinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is frequently dysregulated in cervical cancer.
  • PI3K, a key component, plays a role in oncogenesis and growth factor signaling within cervical cancer.

Purpose of the Study:

  • To review the involvement of the PI3K pathway in cervical cancer.
  • To highlight the significance of PI3K, particularly the class I catalytic subunit PIK3CA, as a therapeutic target.
  • To discuss PI3K inhibitors as potential treatments for cervical cancer.

Main Methods:

  • Literature review focusing on the PI3K pathway in cervical cancer.
  • Analysis of the role of PI3K and its subunits (PIK3CA) in oncogenesis.
  • Examination of existing and potential PI3K inhibitors.

Main Results:

  • The PI3K/Akt/mTOR pathway is implicated in cervical cancer progression.
  • Class I PI3K components, including PIK3CA, are associated with oncogenesis.
  • PIK3CA is identified as a significant pharmacological target.

Conclusions:

  • The PI3K pathway is a critical player in cervical cancer.
  • Targeting PIK3CA presents a therapeutically relevant strategy.
  • PI3K inhibitors show potential for improving cervical cancer treatment outcomes.

More Related Videos

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures08:02

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Published on: July 27, 2022

2.6K
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.0K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K